InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,723.20
(
0.00%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.10
(
-0.13%
)
Bitcoin
61,869.39
(
-1.66%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

LUMA14

Send PM Follow Ignore
Followers 8
Posts 508
Boards Moderated 0
Alias Born 07/04/2014

LUMA14

Re: Jesspro post# 55425

Friday, 10/24/2014 4:51:30 AM

Friday, October 24, 2014 4:51:30 AM

Post# of 80490
Great sponsored study! Great found by Jaybe!

Thanks for this.
Looks very positiv.
Its a win win study.
No or low cost for ARIAD.
Low risks for the doctors.
Possible great reputation for the hospital and the doctors.
Possible help for patients fully therapied, with no other view of help.
Practical use of the wide spread genetic targets for ponatinib proven by scientific studies.
Clinical study at wide spread cancer types.
High hope for success of impact by Ponatinib.

Short runtime of the study.
=> Quick response of data for a much bigger market for Ponatinib!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up